Successful rituximab treatment of an EBV-related lymphoproliferative disease arising after autologous transplantation for angioimmunoblastic T-cell lymphoma

Hematol J. 2002;3(6):317-20. doi: 10.1038/sj.thj.6200202.

Abstract

Rituximab treatment of B-cell lymphoproliferative disease following transplantation is being evaluated. We describe an Epstein-Barr virus-related B-cell lymphoma that developed in a 55-year-old woman, one year after autologous transplantation for relapsing angioimmunoblastic T-cell lymphoma. Complete remission was achieved after four cycles of rituximab and reduced-dose CHOP. This case is discussed in the context of severe immunodepression. Monoclonal anti-CD20 antibodies might restore a balance between T-cell immunosurveillance and EBV proliferation in B-cells,

Publication types

  • Case Reports

MeSH terms

  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Murine-Derived
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Epstein-Barr Virus Infections / complications*
  • Epstein-Barr Virus Infections / etiology
  • Female
  • Humans
  • Immunoblastic Lymphadenopathy / complications
  • Immunoblastic Lymphadenopathy / therapy
  • Lymphoma, B-Cell / etiology
  • Lymphoma, B-Cell / therapy*
  • Lymphoma, B-Cell / virology
  • Lymphoma, T-Cell / complications
  • Lymphoma, T-Cell / therapy
  • Middle Aged
  • Neoplasms, Second Primary / etiology
  • Neoplasms, Second Primary / therapy
  • Neoplasms, Second Primary / virology
  • Peripheral Blood Stem Cell Transplantation / adverse effects*
  • Rituximab
  • Transplantation, Autologous

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Murine-Derived
  • Rituximab